Referencia número: HY-179528

DIM-3,5-Cl2

Revisión del cliente

Based on 1 Customer Validation

DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with K_D values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.18%
No. CAS: 2595179-74-9
Fòrmula: C₂₃H₁₆Cl₂N₂
Peso molecular:391.29

Almacenamiento:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

DIM-3,5-Cl2 Chemical Structure

No. CAS: 2595179-74-9

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[2]^[1]

Nur77/NR4A1

7.7 μM (Kd)

Nurr1/NR4A2

12 μM (Kd)

Caspase 3

Bcl-2

Ver todos los productos específicos de isoformas Nuclear Hormone Receptor 4A/NR4A :

Ver todos los productos específicos de isoformas Glutathione Peroxidase :

GPX1
GPX4

Ver todos los productos específicos de isoformas Bcl-2 Family :

Ver todos los productos específicos de isoformas Caspase :

In Vitro

DIM-3,5-Cl2 (2.5-15 μM) potently inhibits the viability of human MDA-MB-231, MDA-MB-468, and mouse 4T1 TNBC cells^[1].
DIM-3,5-Cl2 (7-15 μM; 24 h for MDA-MB-231, MDA-MB-468; 10-15 μM; 24 h for 4T1) induces apoptosis in human MDA-MB-231, MDA-MB-468, and mouse 4T1 TNBC cells via induction of cleaved PARP and cleaved caspase-3, and downregulation of pro-survival proteins BCL-2, full-length PARP, and full-length caspase-3^[1].
DIM-3,5-Cl2 (7-15 μM; 24 h for MDA-MB-231, MDA-MB-468; 10-15 μM; 24 h for 4T1) modulates ferroptosis-related proteins in human MDA-MB-231, MDA-MB-468, and mouse 4T1 TNBC cells by decreasing GPX4 and SLC7A11 expression, and inducing CD71 expression at lower/mid concentrations (7, 10 μM) while decreasing CD71 at higher concentrations (12, 15 μM)^[1].
DIM-3,5-Cl2 (10-12 μM; 24 h) downregulates pro-oncogenic proteins EGFR, β1-integrin, and c-Myc in human MDA-MB-231 TNBC cells^[1].
DIM-3,5-Cl2 (12 μM; 16 h) potently induces ROS formation in human MDA-MB-231, MDA-MB-468, and mouse 4T1 TNBC cells^[1].
DIM-3,5-Cl2 (12 μM; 16 h) potently induces lipid peroxidation in human MDA-MB-231, MDA-MB-468, and mouse 4T1 TNBC cells^[1].
DIM-3,5-Cl2 (12 μM; 24 h) has its mediated downregulation of CD71, GPX4, and SLC7A11 in human MDA-MB-231 TNBC cells reversed by the ferroptosis inhibitor Ferrostatin-1 (HY-100579), confirming DIM-3,5-Cl2 acts via a ferroptotic pathway^[1].
DIM-3,5-Cl2 (7-10 μM; 1, 2, 4, 6 h) time-dependently induces CD71 protein and CD71 mRNA expression in human MDA-MB-231 TNBC cells, with protein induction at 6 h and mRNA peaking at 4 h^[1].
DIM-3,5-Cl2 (15 μM; 24 h) induces CD71 protein expression in NR4A1/NR4A2-expressing TNBC PDxO models (BCM-HCI-3561, BCM-4175)^[1].
DIM-3,5-Cl2 (10 μM) has mediated induction of CD71 promoter activity in human MDA-MB-231 TNBC cells dependent on NR4A1 and NR4A2 expression, as knockdown of either receptor abrogates the induction^[1].
DIM-3,5-Cl2 (10 μM; 4-24 h) time-dependently induces Sp1, Sp4, and CD71 protein expression in human MDA-MB-231 TNBC cells, and CD71 expression is dependent on Sp1 and Sp4 expression, as knockdown of either transcription factor decreases CD71 levels^[1].
DIM-3,5-Cl2 (0.25-20 μM; 48 h) potently inhibits proliferation of IHEEC cells (IC₅₀ = 7.34 μM) and IHESC cells (IC₅₀ = 5.78 μM) after 48 h of treatment^[2].
DIM-3,5-Cl2 (6.5 μM; 24 h) significantly inhibits migration of both IHEEC and IHESC cells^[2].
DIM-3,5-Cl2 (6.5-13 μM; 24 h) modulates expression of pro-endometriotic pathway proteins in a cell-type specific manner, downregulating growth, fibrosis, and epithelial-to-mesenchymal transition (EMT) markers, upregulating apoptotic markers, and reducing NR4A1/NR4A2 levels in both IHEEC and IHESC cells^[2].
DIM-3,5-Cl2 (13 μM; 12 h) reduces expression of fibrosis and EMT markers (COL1A1, N-cadherin, TWIST1) and disrupts actin filament structures in both IHEEC and IHESC cells^[2].
DIM-3,5-Cl₂ (5-10 μM; 24 h) decreases NR4A1, Sp1, and PD-L1 protein expression in SW480 human colon cancer cells^[3].
DIM-3,5-Cl₂ (2.5-7.5 μM; 24 h) decreases NR4A1, Sp1, and PD-L1 protein expression in RKO human colon cancer cells^[3].
DIM-3,5-Cl₂ (2.5-7.5 μM; 24 h) decreases NR4A1, Sp1, and PD-L1 protein expression in MC-38 murine colon cancer cells^[3].
DIM-3,5-Cl₂ (7.5 μM; 3 h) reduces the binding of NR4A1, Sp1, and PolII to the GC-rich proximal promoter of the PD-L1 gene in MC-38 murine colon cancer cells^[3].
DIM-3,5-Cl₂ (10 μM; 3 h) reduces the binding of NR4A1, Sp1, and PolII to the GC-rich proximal promoter of the PD-L1 gene in SW480 human colon cancer cells^[3].
DIM-3,5-Cl₂ (7.5 μM; 3 h) reduces the binding of NR4A1, Sp1, and PolII to the GC-rich proximal promoter of the PD-L1 gene in RKO human colon cancer cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Human MDA-MB-231, MDA-MB-468, and mouse 4T1 triple negative breast cancer (TNBC) cells
Concentration:

7, 10, 12, 15 μM (MDA-MB-231, MDA-MB-468); 10, 12, 15 μM (4T1)
Incubation Time:

24 h
Result:

Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12 μM in MDA-MB-231 cells.
Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12, 15 μM in MDA-MB-468 cells.
Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 10, 12, 15 μM in 4T1 cells.\nDecreased GPX4 and SLC7A11 protein levels at 7, 10, 12 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12 μM in MDA-MB-231 cells.
Decreased GPX4 and SLC7A11 protein levels at 7, 10, 12, 15 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12, 15 μM in MDA-MB-468 cells.
Decreased GPX4 and SLC7A11 protein levels at 10, 12, 15 μM; induced CD71 protein levels at 10, 12, 15 μM in 4T1 cells.

Western Blot Analysis^[1]

Cell Line:

Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration:

10, 12 μM
Incubation Time:

24 h
Result:

Decreased expression of EGFR, β1-integrin, and c-Myc in MDA-MB-231 cells.

Western Blot Analysis^[1]

Cell Line:

Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration:

12 μM
Incubation Time:

24 h
Result:

Ferrostatin-1 significantly inhibited compound-mediated downregulation of CD71, GPX4, and SLC7A11 in MDA-MB-231 cells.

Western Blot Analysis^[1]

Cell Line:

Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration:

10 μM
Incubation Time:

4, 6, 24 h
Result:

Knockdown of Sp1 or Sp4 alone decreased CD71 protein expression in MDA-MB-231 cells.
Induced Sp1, Sp4, and CD71 protein expression in MDA-MB-231 cells at 4, 6, and 24 h, with increasing induction observed over time.

Cell Migration Assay^[2]

Cell Line:

Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration:

6.5 μM
Incubation Time:

24 h
Result:

Significantly reduced migration of IHEEC and IHESC cells into the scratch wound area compared to vehicle controls, as measured by relative migration percentage.

Western Blot Analysis^[2]

Cell Line:

Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration:

6.5 μM; 13 μM
Incubation Time:

24 h
Result:

Significantly decreased protein levels of EGFR, mTOR, phospho-mTOR, β1-integrin, CTGF, FN, COL1A1, TWIST1, Slug, Snail, Vimentin, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHEEC cells.
Significantly increased protein levels of cleaved poly(ADP-ribose) polymerase (C-PARP) and claudin-1 in IHEEC cells.
Had no significant effect on ERβ levels in IHEEC cells.
Significantly decreased protein levels of mTOR, phospho-mTOR, β1-integrin, ERβ, CTGF, COL1A1, TWIST1, Slug, Snail, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHESC cells.
Significantly increased protein levels of C-PARP and claudin-1 in IHESC cells.
Had no significant effect on EGFR, FN, or α-SMA levels in IHESC cells.

Immunofluorescence^[2]

Cell Line:

Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration:

13 μM
Incubation Time:

12 h
Result:

Significantly reduced fluorescence intensity of COL1A1, N-cadherin, and TWIST1 compared to untreated controls in both IHEEC and IHESC cells.
Caused a substantial decrease in filamentous actin structures in treated cells as shown by phalloidin staining.

In Vivo

DIM-3,5-Cl2 (2.5 mg/kg; i.p.; daily; 34 consecutive days) administered at 2.5 mg/kg daily for 34 days significantly reduces endometriotic lesion growth, suppresses cellular proliferation, increases apoptosis, downregulates Nr4a1 and Nr4a2 in lesions, and does not induce overt toxicity in a surgically induced Mus musculus endometriosis model^[2].
DIM-3,5-Cl2 (2.5-7.5 mg/kg/day; i.p.; daily; 21 days) significantly inhibits MC-38 colon tumor growth in syngeneic C57BL/6 mice, downregulates tumor PD-L1 expression, and reverses T-cell exhaustion in both TILs and splenic CD8⁺ T-cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

FVB/NJ (female, 6 weeks old, surgically induced endometriosis)^[2]
Dosage:

2.5 mg/kg
Administration:

i.p.; daily; 34 consecutive days
Result:

Significantly reduced ectopic lesion volume compared to vehicle control.
Significantly inhibited lesion growth as measured by luciferase imaging, while vehicle-treated mice showed continuous lesion growth.
Significantly reduced Ki-67 expression in stromal cells of ectopic lesions; Ki-67 expression in epithelial cells was not significantly affected.
Significantly increased TUNEL-positive (apoptotic) cells in ectopic lesions.
Significantly reduced Nr4a1 expression in both epithelial and stromal cells of ectopic lesions; significantly reduced Nr4a2 expression in stromal cells, with no significant effect on epithelial Nr4a2 expression.
Did not cause body weight loss, and liver panel analysis showed no evidence of liver damage compared to vehicle control.

Animal Model:

C57BL/6 (female, 4-6 weeks old, subcutaneous implantation of MC-38 colon cancer cells)^[3]
Dosage:

2.5 mg/kg/day; 7.5 mg/kg/day
Administration:

i.p.; daily; 21 days
Result:

Significantly decreased tumor volumes and tumor weights relative to controls.
Showed no treatment-related toxicity, with treated mice showing a slight increase in body weight.
Decreased expression of NR4A1 and PD-L1 in tumor lysates at 2.5 mg/kg/day dose.
Significantly increased the percentage of CD8⁺ T-cells in tumor-infiltrating lymphocytes (TILs) at 2.5 mg/kg/day dose.
Decreased the percentage of CD8⁺ T-cells expressing the T-cell exhaustion markers PD-1, 2B4, and TIM3, and decreased the percentage of CD8⁺ T-cells co-expressing PD-1 and TIM3 in TILs at 2.5 mg/kg/day dose.
Decreased mRNA expression of NR4A1, TOX, TOX2, and NFAT, and increased mRNA expression of interferon γ, granzyme B, perforin, and T-Bet in CD8⁺ T-cells isolated from TILs at 2.5 mg/kg/day dose.
Significantly increased cell percentages, decreased the percentage of cells expressing PD-1, 2B4, TIM3, and PD-1/TIM3, increased the percentage of Treg cells, increased the percentage of cells expressing T-Bet and TOX/TOX2, and decreased the percentage of cells expressing NFAT1 in splenic CD8⁺ T-cells at 2.5 mg/kg/day dose.

Chemical Information

No. CAS 2595179-74-9
Appearance Solid
Peso molecular 391.29
Fòrmula C₂₃H₁₆Cl₂N₂
Color White to off-white
SMILES

ClC1=CC(Cl)=CC(C(C2=CNC3=C2C=CC=C3)C4=CNC5=C4C=CC=C5)=C1
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (255.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5556 mL

12.7782 mL

25.5565 mL

5 mM

0.5111 mL

2.5556 mL

5.1113 mL

10 mM

0.2556 mL

1.2778 mL

2.5556 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (300 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Oany AR, et al. Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer. Cell Death Dis. 2025 Nov 3;16(1):776. [Content Brief]

[2]. Tsui WNT, et al. Dual Targeting of Orphan Nuclear Receptors NR4A1 and NR4A2 for Nonhormonal Endometriosis Therapy. Endocrinology. 2025;166(11):bqaf144. [Content Brief]

[3]. Mohankumar K, et al. Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion. Cancer Immunol Immunother. 2023;72(12):3985-3999. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5556 mL	12.7782 mL	25.5565 mL	63.8912 mL
	5 mM	0.5111 mL	2.5556 mL	5.1113 mL	12.7782 mL
	10 mM	0.2556 mL	1.2778 mL	2.5556 mL	6.3891 mL
	15 mM	0.1704 mL	0.8519 mL	1.7038 mL	4.2594 mL
	20 mM	0.1278 mL	0.6389 mL	1.2778 mL	3.1946 mL
	25 mM	0.1022 mL	0.5111 mL	1.0223 mL	2.5556 mL
	30 mM	0.0852 mL	0.4259 mL	0.8519 mL	2.1297 mL
	40 mM	0.0639 mL	0.3195 mL	0.6389 mL	1.5973 mL
	50 mM	0.0511 mL	0.2556 mL	0.5111 mL	1.2778 mL
	60 mM	0.0426 mL	0.2130 mL	0.4259 mL	1.0649 mL
	80 mM	0.0319 mL	0.1597 mL	0.3195 mL	0.7986 mL
	100 mM	0.0256 mL	0.1278 mL	0.2556 mL	0.6389 mL

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

DIM-3,5-Cl2

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Ver todos los productos específicos de isoformas Nuclear Hormone Receptor 4A/NR4A

Ver todos los productos específicos de isoformas Glutathione Peroxidase

Ver todos los productos específicos de isoformas Bcl-2 Family

Ver todos los productos específicos de isoformas Caspase

Actividad biológica

Chemical Information

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

DIM-3,5-Cl2 Related Classifications

HY-179528 Related Classifications